ACTG 5178

ACTG 5178

• 批准号: 7378883
• 负责人: Mark Sebastian Sulkowski
• 金额: $ 10.55万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378883
• 关键词: ACTG; 5178

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase II, open-label, two-arm, long-term maintenance therapy study. This trial is designed to study whether long-term maintenance with pegylated-interferon alfa-2a (PEG-IFN) reduces the rate of liver fibrosis progression in subjects with HCV/HIV co-infection who have failed to achieve or maintain HCV loads below the limit of detection during treatment with PEG-IFN plus ribavirin. Both HCV treatment na¿¿ve and previously treated subjects will be enrolled.

该子项目是由NIH/NCRR资助的许多子项目之一。研究人员的研究是II期，两臂的长期维护治疗研究。 HCV/HIV共同感染的受试者在使用PEG-IFN加上Ribavirin治疗期间将HCV载荷保持在检测极限之下。挥之不去VE和先前治疗的受试者将被招募。